USANA Health Sciences Files 8-K on Financial Condition & Operations

TL;DR

**USANA just dropped an 8-K on financials, get ready for an update on their performance.**

AI Summary

USANA Health Sciences, Inc. filed an 8-K on February 6, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the health and trajectory of the business. For shareholders or potential buyers, this matters because it offers current financial insights that could influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with the latest financial health update for USANA Health Sciences, directly impacting their assessment of the company's performance and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks.

Analyst Insight

A smart investor would review the full details of the 'Results of Operations and Financial Condition' once they become available to assess USANA's recent performance and adjust their investment thesis accordingly.

Key Numbers

• 001-35024 — Commission File Number (identifies USANA's filings with the SEC)
• 87-0500306 — IRS Employer Identification Number (identifies USANA for tax purposes)

Key Players & Entities

• USANA HEALTH SCIENCES, INC. (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — where USANA's Common Stock is registered
• 001-35024 (dollar_amount) — Commission File No.
• 87-0500306 (dollar_amount) — IRS Employer Identification No.
• February 6, 2024 (date) — Date of Report (Date of Earliest Event Reported)

Forward-Looking Statements

• USANA Health Sciences will likely release detailed financial statements soon. (USANA HEALTH SCIENCES, INC.) — high confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 per value per share USNA New York S

Filing Documents

• a53892955.htm (8-K) — 30KB
• a53892955ex99_1.htm (EX-99.1) — 223KB
• a53892955ex99_2.htm (EX-99.2) — 93KB
• logo.jpg (GRAPHIC) — 8KB
• 0001157523-24-000176.txt ( ) — 520KB
• usna-20240206.xsd (EX-101.SCH) — 4KB
• usna-20240206_lab.xml (EX-101.LAB) — 22KB
• usna-20240206_pre.xml (EX-101.PRE) — 16KB
• a53892955_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 6, 2024, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 30, 2023. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated February 6, 2024 (furnished herewith). 99.2 Management Commentary provided by USANA Health Sciences, Inc. dated February 6, 2024 (furnished herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. USANA HEALTH SCIENCES, INC. By: /s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer Date: February 6, 2024 Exhibit Index Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated February 6, 2024 (furnished herewith) . 99.2 Management Commentary provided by USANA Health Sciences, Inc. dated February 6, 2024 (furnished herewith) . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

View Full Filing

View this 8-K filing on SEC EDGAR